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Key questions
What is already known about this subject?
 ► Heart failure (HF) prevalence is increasing and it 
is a major economic burden to the national health 
service (NHS). European society of cardiology (ESC)9 
and the national institute for health and care ex-
cellence (NICE) guidelines recommend a multidis-
ciplinary HF specialist team approach to reduce 
mortality and hospitalisation. However, there is very 
little data demonstrating the effectiveness of this 
approach in a real world setting within a district 
general hospital (DGH).
What does this study add?
 ► This study shows that the introduction of an integrat-
ed heart failure service (IHFS) into a medium- sized 
DGH can lead to better patient care, with statistically 
significant reductions in 30- day mortality and HF- 
related readmissions in patients with HFpEF.
How might this impact on clinical practice?
 ► Management of HF by an IHFS improves clinical care 
and patient outcome. An IHFS can be established 
with modest resources and limited service redesign. 
We believe this model of care should become rou-
tine throughout the NHS.
AbstrAct
Objectives Assessing the impact of a new integrated 
heart failure service (IHFS) in a medium- sized district 
general hospital (DGH) on heart failure (HF) mortality, 
readmission rates, and provision of HF care.
Methods A retrospective, observational study 
encompassing all patients admitted with a diagnosis of HF 
over two 12- month periods before (2012/2013), and after 
(2015/2016) IHFS establishment.
Results Total admissions for HF increased by 40% (385 
vs 540), with a greater number admitted to the cardiology 
ward (231 vs 121). After IHFS implementation, patients 
were more likely to see a cardiologist (35.1% vs 43.7%, 
p=0.009), undergo echocardiography (70.1% vs 81.5%, 
p<0.001), be initiated on all three disease modifying HF 
medications (angiotensin- converting enzyme inhibitors 
(ACEi), angiotensin II receptor blockers (ARB) and 
mineralocorticoid receptor antagonists (MRA)) in the heart 
failure with reduced ejection fraction (HFrEF) group (42% 
vs 99%, p<0.001) and receive specialist HF input (81.6% 
vs 85.4%, p=0.2). Both 30- day post- discharge mortality 
and HF related readmissions were significantly lower in 
patients with heart failure with preserved ejection fraction 
(HFpEF) (8.9% vs 3.1%, p=0.032, 58% reduction, p=0.043 
respectively) with no- significant reductions in all other 
HF groups. In- patient mortality was similar. Length of 
stay in Cardiology wards increased from 8.4 to 12.7 days 
(p<0.001).
Conclusion Establishment of an IHFS within a DGH with 
limited resources and only a modest service re- design has 
resulted in significantly improved provision of specialist 
in- patient care, use of HFrEF medications, early heart 
failure nurse follow- up, and is associated with a reduction 
in early mortality, particularly in the HFpEF cohort, and HF 
related readmissions.
IntROduCtIOn
Heart failure (HF) is a complex clinical 
syndrome characterised by symptoms and 
signs caused by a structural and/or functional 
cardiac abnormality, leading to a reduction in 
cardiac output and/or elevated intracardiac 
pressures.1 2 In the UK, an estimated 900 000 
people live with HF, and it remains one of 
the leading causes of recurrent hospital 
admissions, particularly in the elderly.3 In 
2014–2015, the ‘national heart failure audit’ 
reported nearly 57 000 admissions in England 
and Wales, with an average length of stay of 
11 days at a cost of approximately £3000 per 
admission. In- hospital mortality was 9.6%, 
30- day mortality 20% and mortality at 1 year 
was 30%.4
Torbay and South Devon covers an area 
of 350 square miles and includes both 
rural communities and urban centres. It 
is a medium- sized district general hospital 
(DGH) within an integrated organisation 
and provides acute healthcare services to a 
resident population of approximately 300 
000, increasing by up to 100 000 during the 
holiday season.5 Torbay’s population is elderly 
with 26.5% over 65 years of age (England 
national average 18.1%) and this proportion 
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is expected to increase to 32% by 2030. In addition, it is 
the most deprived local authority area in the South West 
region. People in deprived communities tend to experi-
ence multiple long- term conditions and generally have 
poorer health outcomes.6
With the publication of NICE guidelines on the 
management of HF in 2010,7 we began to develop an 
integrated heart failure service (IHFS) for patients within 
Torbay hospital and across the wider healthcare commu-
nity. The service was introduced in May 2013 with the 
aims of improving the following:
 ► Use of HFrEF medications known to improve survival.
 ► Education for patients and their families.
 ► Provision of home- based care.
 ► Continuity and coordination of care.
 ► Joined- up working between specialties (palliative 
care, elderly care, renal, intermediate care).
 ► Clinical outcomes (reduce mortality and 
readmissions).
The IHFS takes a multidisciplinary approach and 
comprises two cardiologists with an interest in HF, five 
specialist heart failure nurses (HFNs) (two were already 
employed within primary care and three (2.4 whole- time- 
equivalent (WTE)) were new appointments) together 
with administrative and audit support. HFN training 
involved an 18- month rotation between the hospital and 
community prior to establishment of a single hospital- 
based, and four community- based HFNs (total 4.4 WTE).
The IHFS actively identifies patients admitted with 
suspected HF using B- type natriuretic peptide (BNP) and 
automated email alerts for patients with known HF. The 
HFNs review these patients and discuss them with the 
‘cardiologist of the week’. Together, they identify patients 
suitable for transfer to the cardiology ward. Furthermore, 
all in- patients are discussed formally at the weekly HF 
multidisciplinary team (MDT). This provides all patients 
with specialist consultant input, either by face- to- face 
review on the HF ward, or in discussion with the HFNs.
Following discharge (pre- IHFS and post- IHFS), 
patients are scheduled for urgent outpatient consultant 
clinic review, which usually occurs within 6 weeks (due 
to high demand). However, the new IHFS aims to also 
provide specialist HFN review in the community for all 
HF patients within 2 weeks of discharge.
There is particular focus on improving coding, 
confirming subtype, providing patient education and 
self- management, providing early HFN review post 
discharge and follow- up, and ensuring a seamless transi-
tion between hospital and community services.
MetHOd
Torbay hospital has participated in the national HF 
audit (NICOR) since its inception in 2007 and over this 
period, has established an effective audit process for 
patients coded as having HF on admission. The diagnosis 
is confirmed when a patient presents with appropriate 
signs and symptoms, with echocardiographic abnormality 
and elevation in N- terminal B- type pro B- type natriuretic 
peptide (NT pro- BNP). In those patients who have not 
had an in- patient or recent (<12 months) echocardi-
ogram, clinical assessment with the aid of Chest X- ray 
(CXR) and 12- lead ECG is made.
All admissions with a coded diagnosis of HF were 
reviewed for each 12- month period (01/04/2012–
31/03/2013, n=420 and 01/04/2015–31/03/2016, 
n=576) (see table 1). Some admissions were read-
missions<30 days (35 and 36, respectively) and were 
excluded from the analysis (as these would be repre-
sented in the final readmission rates). Data from the 
remaining patients were attained by review of medical 
notes, echocardiograms, blood results and information 
from the integrated health care system (IHCS). Of total 
admissions, 350 patients in 2012/2013 and 505 patients 
in 2015/2016 had undergone echocardiography allowing 
HF subtype to be confirmed (HFrEF—ejection fraction 
<40% without prior significant valve disease, HFpEF—
ejection fraction >40% with evidence of diastolic dysfunc-
tion, and valvular heart failure (VHF)—presence of 
at least moderate- severe aortic or mitral valve disease). 
Analysis of in- patient deaths and readmissions within 30 
days of discharge was undertaken to confirm the cause of 
death and the clinical reason for readmission. In some 
cases this required additional discussion with the General 
Practitioner (GP).
Statistical analysis
Statistical analysis of mortality and readmission rates was 
performed using the χ2 test. Length- of- stay analysis was 
performed using a non- related t- test. Due to the single- 
centre nature of this study and relatively small patient 
numbers, statistical power is decreased.
Patient and public involvement
As a retrospective, observational study of a service re- de-
sign, patients and the public were not directly involved in 
the design of this study.
ReSultS
Table 1 shows the total of suspected and confirmed HF 
admissions for the 2012/2013 and 2015/2016 cohorts. 
Over this period, admissions increased 40% from 385 to 
540 patients. Patient morbidity data is shown in table 2. 
Patients in the two cohorts were of similar age but in the 
2015/2016 cohort were more symptomatic on admission 
(New York Heart Association (NYHA) 3 or 4, 89.4% vs 
74.5%), more co- morbid, and had worse renal function 
(mean serum creatinine 129 vs 123 mmol/L). There 
were also more likely to be admitted to a cardiology ward 
(31.4% vs 42.8%, p<0.001), be seen by a cardiologist 
(35.1% vs 43.7%, p=0.009), receive specialist HF in- pa-
tient care (81.6% vs 85.4%, p=0.12), undergo echocardi-
ography (70.1% vs 81.5%, p<0.001), and receive an early 
post- discharge home visit from an HFN (28% vs 57%, 
p<0.001) (table 3). In the HFrEF group, the use of all 
three disease modifying HF medications (ACE-/ARB, 
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b- blockers and MRA) on discharge significantly increased 
from 42% in 2012/2013 to 99% in 2015/2016 (p<0.001). 
Length of stay in hospital increased from 7.7 to 9.2 days 
in 2015/2016 (p=0.010).
Mortality
Mortality data is shown in table 1. The 2015/2016 cohort 
had a non- significant, lower overall mortality (20.0% vs 
18.3%, p=0.18), most noticeable in the HFpEF group 
(16.3% vs 13.3%, p=0.435), and to a lesser extent in the 
HFrEF group (18.5% vs 17.1%, p=0.744) but remained 
high and similar for VHF patients (20.6% vs 21.2%, 
0.941). In- patient mortality was similar in both cohorts. 
Table 4 shows that the primary cause of death in both 
cohorts was due to HF (72.3% in 2012/2013 and 62.5% 
in 2015/2016), the remainder often being related to 
hospital acquired chest infection. Following discharge, 
30- day mortality was reduced by 36%, from 8.9% to 5.7% 
(p=0.09) in the 2015/2016 cohort, largely driven by a 
statistically significant 65.2% reduction in patients with 
HFpEF (8.9% vs 3.1%, p=0.032).
Readmissions
Readmission data is shown in tables 1 and 5. There was 
a non- significant signal of lower 30- day readmission rate 
(21.6% vs 20.1%, p=0.6). This was seen in all three HF 
subtypes, but was most marked in patients with HFpEF 
(21.0% vs 18.5%, p=0.630) and VHF (25.0% vs 21.9%, 
p=0.659).
The most notable differences were seen in readmissions 
related to HF (10.7% vs 8.3%, p=0.264), and the reduc-
tion reached statistical significance for HF- related read-
missions in the HFpEF group (10.5% vs 4.3%, p=0.043).
CaRdIOlOgy veRSuS nOn-CaRdIOlOgy
Clinical features
Over the two periods, there was an increase in both the 
number of patients (121 vs 231) and in the proportion 
of the total HF admissions managed in the cardiology 
ward (31.4% vs 42.8%, p<0.001). Before the introduc-
tion of IHFS, patients admitted into the cardiology ward 
rather than a general medical ward tended to be younger 
(76 vs 81 years average) and more clinically unwell as 
judged by proportion of patients in NYHA 3 or 4 (78% 
vs 72.7%), number of co- morbidities, and renal func-
tion (mean serum creatinine 133 vs 123 mmol/L). By 
2015–2016, patients managed in the cardiology ward 
were of similar ages (78 vs 80 years average), with an 
even higher proportion in NYHA 3 or 4 (91%), greater 
co- morbidity, and worse renal function (mean serum 
creatinine 142 mmol/L). Table 2 also shows the change 
in type of HF admitted, with a marked increase in 
numbers of patients with HFrEF and VHF (HFrEF+104%, 
HFpEF +41%, VHF+190%). Length of stay was similar in 
2012/2013 for patients admitted to the cardiology ward 
and general medical wards (8.4 vs 7.3 days (p=0.164) but 
by 2015/2016, had increased dramatically in patients 
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Table 2 Morbidity data
All HF Admissions HFrEF HFpEF VHF
2012/2013 2015/2016 2012/2013 2015/2016 2012/2013 2015/2016 2012/2013 2015/2016
Pre- IHFS Post- IHFS Pre- IHFS Post- IHFS Pre- IHFS Post- IHFS Pre- IHFS Post- IHFS
Coded diagnosis of HF 420 576
Readmissions<30 days 35 36
Confirmed HF admissions 385 540
Subtyped admissions 350 505 135 210 147 181 68 114
  Age 81 80 78 77 82 81 83 83
  Gender F:M 169:216 265:275 49:85 66:144 67:80 110:71 37:31 69:45
  NYHA 1 31 (8.1%) 12 (2.2%) 7 (5%) 5 (2%) 13 (9%) 3 (2%) 7 (1%) 3 (3%)
  NYHA 2 20 (5.2%) 45 (8.3%) 10 (7%) 17 (8%) 6 (4%) 11 (6%) 4 (6%) 11 (10%)
  NYHA 3 54 (14.0%) 209 (38.7)% 15 (11%) 95 (45%) 21 (14%) 63 (35%) 13 (19%) 44 (39%)
  NYHA 4 233 (60.5%) 274 (50.7%) 86 (64%) 93 (44%) 89 (61%) 104 (57%) 35 (51%) 56 (49%)
  Unknown 47 (12.2%) 0 17 (13%) 0 18 (12%) 0 9 (13%) 0
  HTN 140 (36.4%) 278 (51.5%) 47 (35%) 97 (46%) 48 (33%) 106 (56%) 35 (51%) 56 (49%)
  Diabetes 96 (24.9%) 148 (27.4%) 41 (30%) 70 (33%) 39 (27%) 56 (31%) 10 (15%) 14 (13%)
  COPD 58 (15%) 92 (17%) 23 (17%) 36 (17%) 21 (14%) 34 (19%) 9 (13%) 19 (17%)
  Mean serum creatinine 
(mmol/L)
123 129 134 145 119 116 116 123
  HTN unknown 3 0 0 0 3 0 0 0
  Diabetes unknown 2 0 0 0 2 0 0 0
  COPD unknown 0 0 0 0 0 0 0 0
Admissions to cardiology 121 231 56 114 41 58 20 58
  Age 76 78 74 74 79 78 74 83
  Gender F:M 46:75 103:128 21:35 31:83 17:24 36:22 8:12 36:22
  NYHA 1 13 (11%) 3 (1%) 4 (7%) 1 (1%) 5 (12%) 1 (2%) 3 (15%) 1 (2%)
  NYHA 2 5 (4%) 18 (8%) 4 (7%) 8 (7%) 0 3 (5%) 1 (5%) 7 (12%)
  NYHA 3 17 (14%) 107 (46%) 9 (16%) 56 (49%) 5 (12%) 26 (45%) 3 (15%) 25 (43%)
  NYHA 4 77 (64%) 103 (45%) 36 (64%) 49 (43%) 28 (68%) 28 (48%) 10 (50%) 25 (43%)
  Unknown 9 (7%) 0 3 (5%) 0 3 (7%) 0 3 (15%) 0
  HTN 38 (31%) 113 (49%) 20 (36%) 53 (46%) 8 (20%) 31 (53%) 9 (45%) 28 (48%)
  Diabetes 30 (25%) 63 (27%) 16 (29%) 40 (35%) 10 (24%) 15 (26%) 2 (10%) 8 (14%)
  COPD 11 (9%) 35 (15%) 6 (11%) 16 (14%) 3 (7%) 10 (17%) 2 (10%) 9 (16%)
  Mean serum creatinine 
(mmol/L)
133 142 149 155 117 127 121 132
  HTN unknown 2 0 0 0 2 0 0 0
  Diabetes unknown 1 0 0 0 1 0 0 0
  COPD unknown 0 0 0 0 0 0 0 0
COPD, chronic obstructive pulmonary disease; HF, heart failure; HTN, hypertension; IHFS, integrated heart failure service.
admitted to cardiology vs a general medical ward (12.7 vs 
6.6 days, p<0.001) (see tables 1 and 2).
Mortality
Table 1 shows lower mortality rates in both cohorts 
when admitted to a cardiology ward compared with a 
general medical ward (33.2% relative risk reduction in 
2012/2013, 26.6% in 2015/2016). This was seen in both 
HFrEF and HFpEF groups but not in patients with VHF. 
Of note is the 41% improvement in 30- day mortality in 
the 2015/2016 cohort in HFpEF patients managed in the 
cardiology ward (14.6% vs 8.6%, p=0.348).
Readmissions
Readmission rates were lower in patients admitted to 
cardiology wards in both cohorts. The improvement in 
readmission rates in HFpEF patients was driven by the 
large reduction in HF related admissions which fell 
as a proportion from 66.7% in 2012/2013 to 16.7% in 
2015/2016.
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Table 3 HFN community consultations
2012/2013 2015/2016
Pre- IHFS Post- IHFS Y2
Post discharge
(7–14 days)
28% 57% (p<0.001)
Routine care 1104 2250   
  Home 489 891   
  Clinic 593 1371   
  Other 22 21   
HFN, heart failure nurse; IHFS, integrated heart failure service; Y2, 
Second year after IHFS introduction.
Table 4 Causes of in- patient (IP) death
2012/2013 2015/2016
Pre- IHFS Post- IHFS Y2
IP deaths 47/385 (13.4%) 72/540 (13.3%)
Heart failure 34 (72.3%) 45 (62.5%)
Non- heart failure 13 (27.7%) 27 (37.5%)
  Infection 11 18
  ACS 2 7
  Cancer 0 2
ACS, acute coronary syndrome; IHFS, integrated heart failure 
service.
dISCuSSIOn
HF admissions are increasing and this has been well 
documented in the UK over the last decade by NICOR. 
We confirm that over the period 2012/2013–2015/2016 
HF hospitalisations at our DGH have increased by 40%. 
This is likely to reflect not only a real increase in disease 
prevalence in our ageing population, but also improved 
patient identification with greater use of BNP and echo-
cardiograms, and better clinical coding practice. The 
increase was most marked in patients with HFrEF (55.5%) 
and VHF (67.6%). This may reflect societal and demo-
graphic changes, the greater use of echocardiography, 
and an important coding change with some patients with 
‘valvular heart disease’ now being coded as ‘valvular heart 
failure’.
the new IHFS
To effectively manage this growing epidemic of increas-
ingly complex HF admissions, we developed and intro-
duced an IHFS at our hospital with the aim of delivering 
specialist HF care to both hospitalised and community 
patients. Establishing such a service involved gener-
ating a business plan, obtaining financial support for 
2.4 WTE additional HFNs, developing an 18- month 
rotational training programme for our HFNs across 
hospital and community settings, re- writing consultant 
job plans, producing local HF management protocols, 
improving the audit process, establishing an admission 
alert system, and developing a weekly multi- disciplinary 
meeting, including palliative care involvement. We are 
pleased to report that the introduction of the IHFS 
has resulted in more in- patients receiving specialist HF 
care delivered by a cardiologist, on a cardiology ward, 
and with greater use of an early echocardiography. We 
have also seen a dramatic improvement in the use of 
the disease- modifying medications for HFrEF (ACEi/
ARB, ß-blocker, and MRA) at discharge, increasing from 
42% (of those without contraindications) in 2012/2013 
to 99% in 2015/2016 (p<0.001). Perhaps as important 
as this in- patient management is early specialist review 
post- discharge8 and we have significantly increased the 
number of patients receiving a home visit by an HFN 
10–14 days post- discharge (28% vs 57%, p<0.001).
Outcome data
A key aim for the IHFS was to assess hard clinical outcome 
measures in an effort to validate the new model of care. 
We have shown statistically significant reductions in 
30- day mortality and readmission rates in patients with 
HFpEF. We saw a non- significant reduction in mortality 
for patients admitted with HF from 2012/2013 (before 
IHFS) to 2015/2016 (year 3 IHFS).
The principal economic burden of HF relates to the 
expense of hospitalisation. The introduction of an IHFS 
has been associated with a non- significant reduction in 
30- day readmissions. In 2012/2013 we found readmis-
sions were equally likely to be caused directly by HF and 
other non- HF causes. However by 2015/2016, we have 
demonstrated a 16% reduction in readmissions due to 
HF, with most of this benefit seen in patients with HFpEF.
Outcome by HF subtype
HFrEF
There were improvements in the general aspects of HF 
care, with greater specialist input and more patients being 
managed in the cardiology ward, as well as increased use 
of disease modifying medications at discharge. We did not 
observe a statistically significant reduction in mortality or 
readmission rates. We suspect that this is due to the small 
sample size, and the fact that prior to the introduction 
of the IHFS there was already a focus on HFrEF patients, 
including early follow- up. We believe that the benefit 
of the higher numbers of patients on disease- modifying 
medications will be seen beyond 30 days, and will be 
assessing longer term outcomes in further work.
HFpEF
Statistically significant reduction in overall 30- day 
mortality and readmission were seen. These improve-
ments were most pronounced in patients managed on a 
cardiology ward. This is likely due to better optimisation 
of fluid status with a greater emphasis on euvolaemia 
prior to discharge, and related to longer in- patient stays 
in the cardiology ward.
VHF
Patients with VHF have poor prognosis and it is unsur-
prising that mortality in these patients is high and has 
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Table 5 Reason for readmission
2012/2013 2015/2016
Pre- IHFS Post- IHFS Y2
Related to HF 36/338 (10.7%) 39/468 (8.3%) (p=0.264)
Decompensation 31 (86.1%) 32 (82.1%)   
AKI 5 (13.9%) 7 (17.9%)   
Unrelated to HF 37/338 (10.3%) 55/468 (10.9%) (p=0.882)
Infection 13 29   
Other cardiac 5* 8†   
Bleeding 4 4   
Asthma/COPD (non- infective) 3 1   
Falls (no postural drop) 2 2   
Other 10‡ 11§   
*Three due to atrial fibrillation, one non- ST- segment elevation myocardial infarction (NSTEMI), one angina.
†Three due to angina, two atrial flutter, one atrioventricular block, onesupraventricular tachycardia, one NSTEMI.
‡Acute ischaemia, acute kidney injury (AKI) (not taking nephrotoxics), constipation, chronic ischaemia, diverticulosis, lung cancer, 
musculoskeletal pain, no clear pathology, retention, spinal stenosis.
§Bowel obstruction, confusion, constipation, delirium, erratic blood glucose, gout, hypoglycaemia, no clear pathology, non- cardiac chest 
pain, reduced conscious level, submandibular gland swelling.
HF, heart failure; IHFS, integrated heart failure service.
remained unchanged across our two cohorts. There was 
a non- significant reduction in readmissions, but due to 
inconsistent coding of these patients in 2012/2013 it is 
difficult to draw any conclusions from this. We plan to look 
in more detail at this group, and whether more of them 
should be considered for early surgical intervention.
Cardiology versus non-cardiology ward care
Our data point to the benefit of early, specialist cardi-
ology input and admission to a cardiology ward on 30- day 
mortality and readmissions at the expense of longer 
in- patient stay.
For many years, cardiologists and HF specialists have 
focused much of their efforts on HFrEF as it is this 
subtype for which we are currently able to provide effec-
tive pharmacological and device- based therapies. Our 
study showed the greatest impact on patients with HFpEF, 
both with reduced early mortality, and HF readmissions. 
Benefits were greatest in patients managed on a cardi-
ology ward with specialist HF input.
We suggest that this may be related to more aggressive 
and optimised in- patient diuresis, better management of 
atrial fibrillation and other risk factors, improved training 
in self- management, and better provision of early post- 
discharge review and continuing care by a specialist HFN. 
We intend to study this in greater detail.
For patients with VHF we believe that outcomes can be 
improved with early identification and discussion with 
the cardiothoracic team. Work is on- going to assess the 
impact that the IHFS has on identifying and treating this 
group of patients.
limitations
1. As an observational single centre study with relatively 
small patient numbers, our study was underpowered 
to show statistically significant differences in the major 
outcomes.
2. We were unable to confirm the coding diagnosis of 
HF in some patients from each cohort although this 
represents only a small proportion of the patients 
assessed.
3. Some patients did not have an echocardiogram and 
therefore could not be subtyped.
4. BNP was not routinely used in all patients but is used 
in a targeted fashion in patients with clinical concerns 
or diagnostic uncertainty.
COnCluSIOn
Since the introduction of our IHFS we have been pleased 
to see improved identification of patients admitted 
with HF, higher levels of specialist HF in- patient care, 
improved use of disease- modifying HFrEF medications, 
and a greater number of patients benefiting from early 
HFN follow- up. Despite increasing admission numbers, 
of sicker patients, we have seen improved 30- day mortality 
and HF- related readmission rates in the HFpEF cohort. 
This is particularly encouraging, given how difficult it is to 
improve outcomes for this group. An IHFS can be devel-
oped and introduced without major resources and with 
simple service re- design and could be applicable across 
the NHS to improve HF care and clinical outcomes.
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